What is Scipher Medicine?
Scipher Medicine is a precision immunology company dedicated to matching patients with the most effective therapies based on scientific data. Their proprietary network medicine platform, Spectra, analyzes patient molecular data to reveal unique disease signatures and identify optimal treatments from the outset. This approach not only benefits patients with autoimmune diseases by ensuring effective therapy from day one but also generates valuable patient molecular data that aids in the discovery and development of novel therapeutics. The company collaborates with leading payers, healthcare providers, and pharmaceutical firms to deliver these advanced solutions.
How much funding has Scipher Medicine raised?
Scipher Medicine has raised a total of $217.3M across 4 funding rounds:
Series B
$25M
Debt
$350K
Series C
$82M
Other Financing Round
$110M
Series B (2020): $25M with participation from Northpond Ventures, Granpool Innovative Investments, Tachyon Ventures, Khosla Ventures, and Optum Ventures
Debt (2020): $350K led by PPP
Series C (2021): $82M supported by Khosla Ventures, Alumni Ventures, Echo Health Ventures LLC, aMoon, and Northpond Ventures LLC
Other Financing Round (2022): $110M featuring Cowen Healthcare Investments, Laurion Capital Management, Hitachi Ventures, Monashee Investment Management, and Neuberger Berman
Key Investors in Scipher Medicine
Laurion Capital Management
Laurion Capital Management is a New York-based private hedge fund established in 2005, known for its internal research and quantitative investment strategies.
Monashee Investment Management
Monashee Investment Management, founded in 2011 and based in Boston, Massachusetts, is a financial services firm specializing in providing investment advice.
Neuberger Berman
Neuberger Berman is an independent, employee-controlled asset management company founded in 1939, offering global investment solutions across various asset classes.
What's next for Scipher Medicine?
The recent major strategic investment positions Scipher Medicine for accelerated growth and market expansion. This capital infusion is expected to fuel further development of their Spectra platform, enhance commercialization efforts, and potentially broaden their therapeutic focus within autoimmune diseases. The company's trajectory suggests a move towards broader clinical adoption and strategic partnerships, aiming to solidify its role as a leader in data-driven precision medicine. Future endeavors will likely involve leveraging their extensive patient data for drug discovery and development, further integrating their platform into the healthcare ecosystem.
See full Scipher Medicine company page
